What is the Oncotype DX Test?

How is the Oncytype DX test used by doctors?

oncotype DXHas your doctor mentioned the Oncotype DX test for colon cancer? This new diagnostic tool is helping doctors better quantify the risk of a cancer recurring. Doctors will modify your treatment according to your Oncotype DX score to give you the best treatment possible. Dr. Kelly Shimabukuro discusses how doctors use this new test in this short video. Learn why doctors are using the Oncotype DX tests more and more.

To learn more about the Oncotype DX test watch “Oncotype DX Colon Cancer Treatment Decisions” with Dr. Mark F. Kozloff.

Video Transcripts

Kelly A. Shimabukuro, MD: So, the Oncotype DX colon cancer test is a test that can be used, it is a diagnostic tool that I use in terms of helping to better quantify the risk for a cancer recurring in colon cancer. So, I use it particularly in my stage 2 and some of my stage 3 colon cancer patients, who by the number, particularly in stage 2 cancer, by the numbers, they do not have a very high chance of recurring, but there is going to be a group of patients, who may have a higher risk for recurrence than what would be normally estimated based upon the other tools that we may use and some of the tools we use are looking at the pathology report for things we call high risk features, but it is a test that can be sent on a piece of the colon that was resected at the time of their surgery and it takes about two weeks to get the results, but what it does is it gives you a score that is from 0-100 that gives you an idea of what is your risk for cancer recurring and so, it is a useful piece of information for many of my patients and it helps us, you know, the patient and myself make an educated decision about whether to do chemotherapy or not.

Kelly Shimabukuro
Dr. Kelly Shimabukuro is currently the Assistant Clinical Professor of Medicine at the University of California, San Diego department of medicine. She specializes in the management of gastrointestinal cancers including colorectal cancer, pancreatic cancer, esophageal cancer, hepatobiliary cancer and anal cancer. She has a particular interest in hepatocellular cancer and is working closely with our multidisciplinary hepatology team in the management of these patients. She has specialized training in clinical trial design and implementation and is integrating this into her practice.


This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.

© 2020 Cancer Answers LLC